Structured Abstract

Contents

• Preface
• Acknowledgements
• Technical Expert Panel
• Peer Reviewers
• Executive Summary
• Introduction
  • Background
  • Scope and Key Questions
• Methods
  • Topic Development
  • Search Strategy
  • Study Selection
  • Data Extraction
  • Quality Assessment
• Results
  • Overview
  • Key Question 1 What are the Comparative Benefits and Harms of Treating Osteoarthritis With Oral Medications or Supplements?
  • Key Question 1a How do These Benefits and Harms Change With Dosage and Duration of Treatment, and What is the Evidence That Alternative Dosage Strategies, Such as Intermittent Dosing and Drug Holidays, Affect the Benefits and Harms of Oral Medication use?
  • Key Question 2 Do the Comparative Benefits and Harms of Oral Treatments for Osteoarthritis Vary for Certain Demographic and Clinical Subgroups?
  • Key Question 3 What are the Comparative Effects of Coprescribing of H2-Antagonists, Misoprostol, or Proton Pump Inhibitors (PPIs) on the Gastrointestinal Harms Associated With NSAID use?
  • Key Question 4 What are the Comparative Benefits and Harms of Treating Osteoarthritis With Oral Medications as Compared With Topical Preparations?
• Summary and Discussion
  • Discussion
  • Future Research
• References
• Acronyms and Abbreviations
• Glossary
• Appendixes
  • Appendix A Comparable NSAID Dose Levels
  • Appendix B Cyclooxygenase Selectivity of NSAIDs
  • Appendix C Exact Search Strings
  • Appendix D Inclusion and Exclusion Criteria
  • Appendix E Excluded Studies
  • Appendix F Quality Assessment Methods
  • Appendix G Quality Assessment of Trials, Systematic Reviews, and Observational Studies
  • Appendix H Evidence Tables: Oral NSAIDs
  • Appendix I Evidence Tables: Glucosamine and Chondroitin Studies
  • Appendix J Evidence Tables: Topical NSAIDs

Prepared for: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services¹, Contract No. HHSA 290 2007 10057 I. Prepared by: Oregon Evidence-based Practice Center, Oregon Health & Science University, Portland, Oregon

Suggested citation:

Chou R, McDonagh MS, Nakamoto E, Griffin J. Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review. Comparative Effectiveness Review No. 38. (Prepared by the Oregon Evidence-based Practice Center under Contract No. HHSA 290 2007 10057 I) AHRQ Publication No. 11(12)-EHC076-EF. Rockville, MD: Agency for Healthcare Research and Quality. October 2011. www.effectivehealthcare.ahrq.gov/reports/final.cfm.

This report is based on research conducted by the Oregon Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290 2007 10057 I). The findings and conclusions in this document are those of the author(s), who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

1

540 Gaither Road, Rockville, MD 20850; www​.ahrq.gov